Dasabuvir inhibited the phosphorylation of ERK1/2 and downregulated CDK4 and cyclin D1 through targeting ROCK1, thus blocking the progression of ESCC. This evidence concerns the gene MAPK3 and esophageal squamous cell carcinoma.